J.Á. Arranz Arija

PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)

Johann S. de Bono, Ugo De Giorgi, Christophe Massard et al. · Annals of Oncology · 2016 · 53 citations · Full text

Medicine, Oncology, Pharmacology +17

IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

Enrique Grande, Matt D. Galsky, J.Á. Arranz Arija et al. · Annals of Oncology · 2019 · 39 citations · Full text

Medicine, Oncology, Pharmacology +13

E400P in advanced seminoma of good prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification: The Spanish Germ Cell Cancer Group experience

J.Á. Arranz Arija, Xavier García del Muro, Josep Gumà et al. · Annals of Oncology · 2001 · 32 citations

Medicine, Oncology, Pathology +8

Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study

Matt D. Galsky, Margitta Retz, Arlene O. Siefker‐Radtke et al. · Annals of Oncology · 2016 · 28 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base

Regina Gironés, Jorge Aparicio, P. Roure et al. · Clinical & Translational Oncology · 2014 · 21 citations

Medicine, Oncology, Pathology +14